nodes	percent_of_prediction	percent_of_DWPC	metapath
Tirofiban—ITGB3—skin epidermis—skin cancer	0.105	0.165	CbGeAlD
Tirofiban—ITGA2B—endothelium—skin cancer	0.0871	0.137	CbGeAlD
Tirofiban—ITGA2B—blood vessel—skin cancer	0.0803	0.126	CbGeAlD
Tirofiban—ITGB3—endothelium—skin cancer	0.0761	0.12	CbGeAlD
Tirofiban—ITGB3—blood vessel—skin cancer	0.0702	0.111	CbGeAlD
Tirofiban—ITGB3—connective tissue—skin cancer	0.036	0.0567	CbGeAlD
Tirofiban—ITGB3—epithelium—skin cancer	0.0342	0.0538	CbGeAlD
Tirofiban—ITGB3—skin of body—skin cancer	0.0325	0.0512	CbGeAlD
Tirofiban—ITGA2B—lymphoid tissue—skin cancer	0.0301	0.0474	CbGeAlD
Tirofiban—ITGB3—lymphoid tissue—skin cancer	0.0263	0.0414	CbGeAlD
Tirofiban—ITGB3—female reproductive system—skin cancer	0.0254	0.04	CbGeAlD
Tirofiban—ITGA2B—lymph node—skin cancer	0.017	0.0268	CbGeAlD
Tirofiban—ITGB3—lymph node—skin cancer	0.0149	0.0234	CbGeAlD
Tirofiban—ITGA2B—L1CAM interactions—SCN10A—skin cancer	0.0141	0.0928	CbGpPWpGaD
Tirofiban—Haemorrhage intracranial—Temozolomide—skin cancer	0.0116	0.0544	CcSEcCtD
Tirofiban—Haemoglobin decreased—Imiquimod—skin cancer	0.0115	0.0542	CcSEcCtD
Tirofiban—ITGB3—L1CAM interactions—SCN10A—skin cancer	0.0109	0.0715	CbGpPWpGaD
Tirofiban—Hypercholesterolaemia—Imiquimod—skin cancer	0.0084	0.0394	CcSEcCtD
Tirofiban—Swelling—Imiquimod—skin cancer	0.00654	0.0307	CcSEcCtD
Tirofiban—ITGB3—VEGFA-VEGFR2 Pathway—RASA1—skin cancer	0.00572	0.0376	CbGpPWpGaD
Tirofiban—ITGB3—Signaling by VEGF—RASA1—skin cancer	0.00539	0.0355	CbGpPWpGaD
Tirofiban—ITGA2B—Axon guidance—SCN10A—skin cancer	0.00532	0.0351	CbGpPWpGaD
Tirofiban—ITGB3—PDGFR-beta signaling pathway—RASA1—skin cancer	0.00505	0.0332	CbGpPWpGaD
Tirofiban—Haemoglobin decreased—Docetaxel—skin cancer	0.0046	0.0216	CcSEcCtD
Tirofiban—Pain—Vismodegib—skin cancer	0.0046	0.0216	CcSEcCtD
Tirofiban—Myocardial infarction—Imiquimod—skin cancer	0.00436	0.0204	CcSEcCtD
Tirofiban—Chills—Vemurafenib—skin cancer	0.0042	0.0197	CcSEcCtD
Tirofiban—ITGB3—Axon guidance—SCN10A—skin cancer	0.0041	0.027	CbGpPWpGaD
Tirofiban—Haemoglobin—Imiquimod—skin cancer	0.00401	0.0188	CcSEcCtD
Tirofiban—Haemorrhage—Imiquimod—skin cancer	0.00399	0.0187	CcSEcCtD
Tirofiban—ITGA2B—Developmental Biology—SCN10A—skin cancer	0.0038	0.025	CbGpPWpGaD
Tirofiban—Swelling—Fluorouracil—skin cancer	0.00361	0.0169	CcSEcCtD
Tirofiban—Chills—Imiquimod—skin cancer	0.00358	0.0168	CcSEcCtD
Tirofiban—ITGB3—Signaling events mediated by VEGFR1 and VEGFR2—BRAF—skin cancer	0.00356	0.0235	CbGpPWpGaD
Tirofiban—ITGA2B—Integrin-mediated Cell Adhesion—BRAF—skin cancer	0.0034	0.0224	CbGpPWpGaD
Tirofiban—Anaphylactic shock—Vemurafenib—skin cancer	0.00332	0.0156	CcSEcCtD
Tirofiban—Nausea—Vismodegib—skin cancer	0.00319	0.015	CcSEcCtD
Tirofiban—ITGA2B—Hematopoietic Stem Cell Differentiation—IL6—skin cancer	0.00311	0.0205	CbGpPWpGaD
Tirofiban—Myocardial infarction—Bleomycin—skin cancer	0.00309	0.0145	CcSEcCtD
Tirofiban—ITGA2B—Axon guidance—RASA1—skin cancer	0.00306	0.0201	CbGpPWpGaD
Tirofiban—Haematuria—Bleomycin—skin cancer	0.00301	0.0141	CcSEcCtD
Tirofiban—Hypertension—Imiquimod—skin cancer	0.003	0.0141	CcSEcCtD
Tirofiban—ITGB3—Developmental Biology—SCN10A—skin cancer	0.00293	0.0193	CbGpPWpGaD
Tirofiban—ITGA2B—Signaling Pathways—RHOU—skin cancer	0.0029	0.0191	CbGpPWpGaD
Tirofiban—Haemoglobin—Bleomycin—skin cancer	0.00285	0.0134	CcSEcCtD
Tirofiban—Oedema—Imiquimod—skin cancer	0.00283	0.0133	CcSEcCtD
Tirofiban—Haemorrhage—Bleomycin—skin cancer	0.00283	0.0133	CcSEcCtD
Tirofiban—Hyperhidrosis—Imiquimod—skin cancer	0.00274	0.0129	CcSEcCtD
Tirofiban—ITGB3—TGF-beta Signaling Pathway—TERT—skin cancer	0.00265	0.0174	CbGpPWpGaD
Tirofiban—Body temperature increased—Vemurafenib—skin cancer	0.00263	0.0123	CcSEcCtD
Tirofiban—ITGB3—Integrin-mediated Cell Adhesion—BRAF—skin cancer	0.00262	0.0172	CbGpPWpGaD
Tirofiban—Swelling—Docetaxel—skin cancer	0.0026	0.0122	CcSEcCtD
Tirofiban—Chills—Bleomycin—skin cancer	0.00254	0.0119	CcSEcCtD
Tirofiban—Hypersensitivity—Vemurafenib—skin cancer	0.00245	0.0115	CcSEcCtD
Tirofiban—Pain—Imiquimod—skin cancer	0.00242	0.0114	CcSEcCtD
Tirofiban—Myocardial infarction—Fluorouracil—skin cancer	0.0024	0.0113	CcSEcCtD
Tirofiban—Haemoglobin—Temozolomide—skin cancer	0.0024	0.0113	CcSEcCtD
Tirofiban—ITGB3—Hematopoietic Stem Cell Differentiation—IL6—skin cancer	0.0024	0.0158	CbGpPWpGaD
Tirofiban—Haemorrhage—Temozolomide—skin cancer	0.00239	0.0112	CcSEcCtD
Tirofiban—Chills—Dactinomycin—skin cancer	0.00237	0.0111	CcSEcCtD
Tirofiban—ITGB3—Axon guidance—RASA1—skin cancer	0.00236	0.0155	CbGpPWpGaD
Tirofiban—Urticaria—Imiquimod—skin cancer	0.00225	0.0106	CcSEcCtD
Tirofiban—Body temperature increased—Imiquimod—skin cancer	0.00224	0.0105	CcSEcCtD
Tirofiban—ITGB3—Signaling Pathways—RHOU—skin cancer	0.00224	0.0147	CbGpPWpGaD
Tirofiban—Haemoglobin—Fluorouracil—skin cancer	0.00221	0.0104	CcSEcCtD
Tirofiban—Haemorrhage—Fluorouracil—skin cancer	0.0022	0.0103	CcSEcCtD
Tirofiban—Dizziness—Vemurafenib—skin cancer	0.0022	0.0103	CcSEcCtD
Tirofiban—ITGB3—PDGFR-beta signaling pathway—BRAF—skin cancer	0.00219	0.0144	CbGpPWpGaD
Tirofiban—ITGA2B—Developmental Biology—RASA1—skin cancer	0.00218	0.0144	CbGpPWpGaD
Tirofiban—Chills—Temozolomide—skin cancer	0.00214	0.0101	CcSEcCtD
Tirofiban—Hypersensitivity—Imiquimod—skin cancer	0.00209	0.0098	CcSEcCtD
Tirofiban—Headache—Vemurafenib—skin cancer	0.00208	0.00977	CcSEcCtD
Tirofiban—ITGA2B—Focal Adhesion—BRAF—skin cancer	0.00203	0.0134	CbGpPWpGaD
Tirofiban—Oedema—Bleomycin—skin cancer	0.00201	0.00945	CcSEcCtD
Tirofiban—Anaphylactic shock—Bleomycin—skin cancer	0.00201	0.00945	CcSEcCtD
Tirofiban—Nausea—Vemurafenib—skin cancer	0.00197	0.00926	CcSEcCtD
Tirofiban—Thrombocytopenia—Bleomycin—skin cancer	0.00197	0.00925	CcSEcCtD
Tirofiban—Oedema—Dactinomycin—skin cancer	0.00188	0.00881	CcSEcCtD
Tirofiban—Dizziness—Imiquimod—skin cancer	0.00187	0.00879	CcSEcCtD
Tirofiban—Thrombocytopenia—Dactinomycin—skin cancer	0.00184	0.00863	CcSEcCtD
Tirofiban—Hypertension—Temozolomide—skin cancer	0.0018	0.00843	CcSEcCtD
Tirofiban—Headache—Imiquimod—skin cancer	0.00178	0.00833	CcSEcCtD
Tirofiban—Myocardial infarction—Docetaxel—skin cancer	0.00174	0.00814	CcSEcCtD
Tirofiban—Pain—Bleomycin—skin cancer	0.00172	0.00808	CcSEcCtD
Tirofiban—Oedema—Temozolomide—skin cancer	0.0017	0.00797	CcSEcCtD
Tirofiban—Anaphylactic shock—Temozolomide—skin cancer	0.0017	0.00797	CcSEcCtD
Tirofiban—Nausea—Imiquimod—skin cancer	0.00168	0.0079	CcSEcCtD
Tirofiban—ITGB3—Developmental Biology—RASA1—skin cancer	0.00168	0.0111	CbGpPWpGaD
Tirofiban—Thrombocytopenia—Temozolomide—skin cancer	0.00166	0.0078	CcSEcCtD
Tirofiban—ITGB3—Cell surface interactions at the vascular wall—NRAS—skin cancer	0.00166	0.0109	CbGpPWpGaD
Tirofiban—Hyperhidrosis—Temozolomide—skin cancer	0.00164	0.0077	CcSEcCtD
Tirofiban—Pain—Dactinomycin—skin cancer	0.00161	0.00753	CcSEcCtD
Tirofiban—Urticaria—Bleomycin—skin cancer	0.0016	0.0075	CcSEcCtD
Tirofiban—Haemoglobin—Docetaxel—skin cancer	0.0016	0.0075	CcSEcCtD
Tirofiban—Body temperature increased—Bleomycin—skin cancer	0.00159	0.00747	CcSEcCtD
Tirofiban—Haemorrhage—Docetaxel—skin cancer	0.00159	0.00746	CcSEcCtD
Tirofiban—ITGB3—Focal Adhesion—BRAF—skin cancer	0.00157	0.0103	CbGpPWpGaD
Tirofiban—Anaphylactic shock—Fluorouracil—skin cancer	0.00156	0.00734	CcSEcCtD
Tirofiban—Oedema—Fluorouracil—skin cancer	0.00156	0.00734	CcSEcCtD
Tirofiban—ITGA2B—Integrin-mediated Cell Adhesion—HRAS—skin cancer	0.00156	0.0103	CbGpPWpGaD
Tirofiban—ITGB3—VEGFA-VEGFR2 Pathway—NRAS—skin cancer	0.00156	0.0103	CbGpPWpGaD
Tirofiban—Thrombocytopenia—Fluorouracil—skin cancer	0.00153	0.00719	CcSEcCtD
Tirofiban—Body temperature increased—Dactinomycin—skin cancer	0.00148	0.00696	CcSEcCtD
Tirofiban—Hypersensitivity—Bleomycin—skin cancer	0.00148	0.00696	CcSEcCtD
Tirofiban—ITGB3—Signaling by VEGF—NRAS—skin cancer	0.00147	0.00969	CbGpPWpGaD
Tirofiban—Pain—Temozolomide—skin cancer	0.00145	0.00681	CcSEcCtD
Tirofiban—ITGB3—Cell surface interactions at the vascular wall—KRAS—skin cancer	0.00143	0.0094	CbGpPWpGaD
Tirofiban—Chills—Docetaxel—skin cancer	0.00143	0.00669	CcSEcCtD
Tirofiban—ITGA2B—Signaling Pathways—PTCH2—skin cancer	0.00142	0.00934	CbGpPWpGaD
Tirofiban—Hypersensitivity—Dactinomycin—skin cancer	0.00138	0.00649	CcSEcCtD
Tirofiban—ITGB3—PDGFR-beta signaling pathway—NRAS—skin cancer	0.00138	0.00907	CbGpPWpGaD
Tirofiban—Urticaria—Temozolomide—skin cancer	0.00135	0.00633	CcSEcCtD
Tirofiban—Body temperature increased—Temozolomide—skin cancer	0.00134	0.0063	CcSEcCtD
Tirofiban—ITGB3—VEGFA-VEGFR2 Pathway—KRAS—skin cancer	0.00134	0.00884	CbGpPWpGaD
Tirofiban—Pain—Fluorouracil—skin cancer	0.00134	0.00628	CcSEcCtD
Tirofiban—ITGB3—Signaling by VEGF—KRAS—skin cancer	0.00127	0.00834	CbGpPWpGaD
Tirofiban—Hypersensitivity—Temozolomide—skin cancer	0.00125	0.00587	CcSEcCtD
Tirofiban—Urticaria—Fluorouracil—skin cancer	0.00124	0.00583	CcSEcCtD
Tirofiban—Body temperature increased—Fluorouracil—skin cancer	0.00124	0.0058	CcSEcCtD
Tirofiban—ITGB3—Cell surface interactions at the vascular wall—HRAS—skin cancer	0.00121	0.00799	CbGpPWpGaD
Tirofiban—ITGB3—Integrin-mediated Cell Adhesion—HRAS—skin cancer	0.0012	0.00793	CbGpPWpGaD
Tirofiban—Nausea—Bleomycin—skin cancer	0.0012	0.00561	CcSEcCtD
Tirofiban—Hypertension—Docetaxel—skin cancer	0.00119	0.00561	CcSEcCtD
Tirofiban—ITGB3—PDGFR-beta signaling pathway—KRAS—skin cancer	0.00118	0.0078	CbGpPWpGaD
Tirofiban—Hypersensitivity—Fluorouracil—skin cancer	0.00115	0.00541	CcSEcCtD
Tirofiban—ITGB3—VEGFA-VEGFR2 Pathway—HRAS—skin cancer	0.00114	0.00751	CbGpPWpGaD
Tirofiban—Anaphylactic shock—Docetaxel—skin cancer	0.00113	0.0053	CcSEcCtD
Tirofiban—Oedema—Docetaxel—skin cancer	0.00113	0.0053	CcSEcCtD
Tirofiban—Dizziness—Temozolomide—skin cancer	0.00112	0.00527	CcSEcCtD
Tirofiban—Nausea—Dactinomycin—skin cancer	0.00112	0.00523	CcSEcCtD
Tirofiban—Thrombocytopenia—Docetaxel—skin cancer	0.00111	0.00519	CcSEcCtD
Tirofiban—ITGB3—Signaling Pathways—PTCH2—skin cancer	0.00109	0.00719	CbGpPWpGaD
Tirofiban—ITGB3—VEGFA-VEGFR2 Pathway—IL6—skin cancer	0.00109	0.00719	CbGpPWpGaD
Tirofiban—ITGB3—Signaling by VEGF—HRAS—skin cancer	0.00108	0.00709	CbGpPWpGaD
Tirofiban—ITGA2B—Signaling Pathways—GLI2—skin cancer	0.00107	0.00708	CbGpPWpGaD
Tirofiban—ITGA2B—Developmental Biology—CDK4—skin cancer	0.00107	0.00705	CbGpPWpGaD
Tirofiban—Headache—Temozolomide—skin cancer	0.00106	0.00499	CcSEcCtD
Tirofiban—Dizziness—Fluorouracil—skin cancer	0.00103	0.00486	CcSEcCtD
Tirofiban—ITGB3—Signaling by VEGF—IL6—skin cancer	0.00103	0.00679	CbGpPWpGaD
Tirofiban—ITGA2B—Signaling Pathways—MC1R—skin cancer	0.00102	0.00675	CbGpPWpGaD
Tirofiban—ITGA2B—Signaling Pathways—GLI1—skin cancer	0.00101	0.00665	CbGpPWpGaD
Tirofiban—Nausea—Temozolomide—skin cancer	0.00101	0.00473	CcSEcCtD
Tirofiban—ITGB3—TGF-beta Signaling Pathway—TP53—skin cancer	0.00101	0.00664	CbGpPWpGaD
Tirofiban—ITGB3—PDGFR-beta signaling pathway—HRAS—skin cancer	0.00101	0.00663	CbGpPWpGaD
Tirofiban—Headache—Fluorouracil—skin cancer	0.00098	0.0046	CcSEcCtD
Tirofiban—Pain—Docetaxel—skin cancer	0.000966	0.00453	CcSEcCtD
Tirofiban—ITGA2B—Signaling Pathways—SUFU—skin cancer	0.000958	0.00631	CbGpPWpGaD
Tirofiban—ITGA2B—Focal Adhesion—HRAS—skin cancer	0.000935	0.00616	CbGpPWpGaD
Tirofiban—Nausea—Fluorouracil—skin cancer	0.000929	0.00436	CcSEcCtD
Tirofiban—Body temperature increased—Docetaxel—skin cancer	0.000893	0.00419	CcSEcCtD
Tirofiban—ITGA2B—Axon guidance—NRAS—skin cancer	0.000834	0.00549	CbGpPWpGaD
Tirofiban—Hypersensitivity—Docetaxel—skin cancer	0.000832	0.0039	CcSEcCtD
Tirofiban—ITGB3—Signaling Pathways—GLI2—skin cancer	0.000828	0.00545	CbGpPWpGaD
Tirofiban—ITGB3—Developmental Biology—CDK4—skin cancer	0.000824	0.00543	CbGpPWpGaD
Tirofiban—ITGB3—Signaling Pathways—MC1R—skin cancer	0.00079	0.0052	CbGpPWpGaD
Tirofiban—ITGB3—Signaling Pathways—GLI1—skin cancer	0.000778	0.00513	CbGpPWpGaD
Tirofiban—Dizziness—Docetaxel—skin cancer	0.000747	0.0035	CcSEcCtD
Tirofiban—ITGB3—Signaling Pathways—SUFU—skin cancer	0.000738	0.00486	CbGpPWpGaD
Tirofiban—ITGA2B—Signaling Pathways—SHH—skin cancer	0.00073	0.00481	CbGpPWpGaD
Tirofiban—ITGA2B—Signaling Pathways—RASA1—skin cancer	0.000726	0.00478	CbGpPWpGaD
Tirofiban—ITGB3—Focal Adhesion—HRAS—skin cancer	0.00072	0.00474	CbGpPWpGaD
Tirofiban—ITGA2B—Axon guidance—KRAS—skin cancer	0.000718	0.00473	CbGpPWpGaD
Tirofiban—Headache—Docetaxel—skin cancer	0.000707	0.00332	CcSEcCtD
Tirofiban—ITGA2B—Signaling Pathways—SMO—skin cancer	0.000692	0.00456	CbGpPWpGaD
Tirofiban—ITGA2B—Signaling Pathways—PTCH1—skin cancer	0.000692	0.00456	CbGpPWpGaD
Tirofiban—ITGA2B—Signaling Pathways—PTGER4—skin cancer	0.000674	0.00444	CbGpPWpGaD
Tirofiban—Nausea—Docetaxel—skin cancer	0.000671	0.00315	CcSEcCtD
Tirofiban—ITGB3—Axon guidance—NRAS—skin cancer	0.000642	0.00423	CbGpPWpGaD
Tirofiban—ITGA2B—Axon guidance—HRAS—skin cancer	0.00061	0.00402	CbGpPWpGaD
Tirofiban—ITGA2B—Signaling Pathways—FOXO4—skin cancer	0.000595	0.00392	CbGpPWpGaD
Tirofiban—ITGA2B—Developmental Biology—NRAS—skin cancer	0.000595	0.00392	CbGpPWpGaD
Tirofiban—ITGA2B—Axon guidance—IL6—skin cancer	0.000584	0.00385	CbGpPWpGaD
Tirofiban—ITGA2B—Hemostasis—NRAS—skin cancer	0.000584	0.00385	CbGpPWpGaD
Tirofiban—ITGB3—Signaling Pathways—SHH—skin cancer	0.000563	0.00371	CbGpPWpGaD
Tirofiban—ITGB3—Signaling Pathways—RASA1—skin cancer	0.000559	0.00368	CbGpPWpGaD
Tirofiban—ITGB3—Axon guidance—KRAS—skin cancer	0.000553	0.00364	CbGpPWpGaD
Tirofiban—ITGB3—Signaling Pathways—PTCH1—skin cancer	0.000533	0.00351	CbGpPWpGaD
Tirofiban—ITGB3—Signaling Pathways—SMO—skin cancer	0.000533	0.00351	CbGpPWpGaD
Tirofiban—ITGB3—Signaling Pathways—PTGER4—skin cancer	0.000519	0.00342	CbGpPWpGaD
Tirofiban—ITGA2B—Developmental Biology—KRAS—skin cancer	0.000512	0.00337	CbGpPWpGaD
Tirofiban—ITGA2B—Hemostasis—KRAS—skin cancer	0.000502	0.00331	CbGpPWpGaD
Tirofiban—ITGB3—Axon guidance—HRAS—skin cancer	0.00047	0.0031	CbGpPWpGaD
Tirofiban—ITGB3—Signaling Pathways—FOXO4—skin cancer	0.000459	0.00302	CbGpPWpGaD
Tirofiban—ITGB3—Developmental Biology—NRAS—skin cancer	0.000458	0.00302	CbGpPWpGaD
Tirofiban—ITGB3—Axon guidance—IL6—skin cancer	0.00045	0.00296	CbGpPWpGaD
Tirofiban—ITGB3—Hemostasis—NRAS—skin cancer	0.00045	0.00296	CbGpPWpGaD
Tirofiban—ITGA2B—Hemostasis—TP53—skin cancer	0.000447	0.00294	CbGpPWpGaD
Tirofiban—ITGA2B—Developmental Biology—HRAS—skin cancer	0.000435	0.00287	CbGpPWpGaD
Tirofiban—ITGA2B—Hemostasis—HRAS—skin cancer	0.000427	0.00281	CbGpPWpGaD
Tirofiban—ITGA2B—Developmental Biology—IL6—skin cancer	0.000417	0.00274	CbGpPWpGaD
Tirofiban—ITGA2B—Signaling Pathways—TERT—skin cancer	0.000398	0.00262	CbGpPWpGaD
Tirofiban—ITGB3—Developmental Biology—KRAS—skin cancer	0.000395	0.0026	CbGpPWpGaD
Tirofiban—ITGB3—Hemostasis—KRAS—skin cancer	0.000387	0.00255	CbGpPWpGaD
Tirofiban—ITGB3—Hemostasis—TP53—skin cancer	0.000344	0.00227	CbGpPWpGaD
Tirofiban—ITGB3—Developmental Biology—HRAS—skin cancer	0.000335	0.00221	CbGpPWpGaD
Tirofiban—ITGB3—Hemostasis—HRAS—skin cancer	0.000329	0.00217	CbGpPWpGaD
Tirofiban—ITGB3—Developmental Biology—IL6—skin cancer	0.000321	0.00211	CbGpPWpGaD
Tirofiban—ITGA2B—Signaling Pathways—BRAF—skin cancer	0.000315	0.00207	CbGpPWpGaD
Tirofiban—ITGB3—Signaling Pathways—TERT—skin cancer	0.000306	0.00202	CbGpPWpGaD
Tirofiban—ITGB3—Signaling Pathways—BRAF—skin cancer	0.000243	0.0016	CbGpPWpGaD
Tirofiban—ITGA2B—Signaling Pathways—NRAS—skin cancer	0.000198	0.0013	CbGpPWpGaD
Tirofiban—ITGA2B—Signaling Pathways—KRAS—skin cancer	0.00017	0.00112	CbGpPWpGaD
Tirofiban—ITGB3—Signaling Pathways—NRAS—skin cancer	0.000152	0.001	CbGpPWpGaD
Tirofiban—ITGA2B—Signaling Pathways—TP53—skin cancer	0.000151	0.000997	CbGpPWpGaD
Tirofiban—ITGA2B—Signaling Pathways—HRAS—skin cancer	0.000145	0.000954	CbGpPWpGaD
Tirofiban—ITGA2B—Signaling Pathways—IL6—skin cancer	0.000139	0.000913	CbGpPWpGaD
Tirofiban—ITGB3—Signaling Pathways—KRAS—skin cancer	0.000131	0.000864	CbGpPWpGaD
Tirofiban—ITGB3—Signaling Pathways—TP53—skin cancer	0.000117	0.000768	CbGpPWpGaD
Tirofiban—ITGB3—Signaling Pathways—HRAS—skin cancer	0.000112	0.000735	CbGpPWpGaD
Tirofiban—ITGB3—Signaling Pathways—IL6—skin cancer	0.000107	0.000703	CbGpPWpGaD
